Rewiring the brain with cell transplantation in Parkinson's disease

Trends in Neurosciences

Volumn 34, Issue 3, 2011, Pages 124-133

  Gaillard, Afsaneh ^a   Jaber, Mohamed ^a  

^a UNIVERSITÉ DE POITIERS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE;

BEHAVIOR DISORDER; CELL TRANSPLANTATION; CORPUS STRIATUM; DOPAMINE RELEASE; DYSKINESIA; HUMAN; NERVE PROJECTION; NEUROBLAST; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC NERVE CELL;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; HUMANS; NEURAL STEM CELLS; PARKINSON DISEASE; STEM CELL TRANSPLANTATION;

EID: 79952245490     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tins.2011.01.003     Document Type: Review

References (98)

1. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
2. Björklund A. Dopaminergic transplants in experimental parkinsonism: cellular mechanisms of graft-induced functional recovery. Curr. Opin. Neurobiol. 1992, 2:683-689.
3. Winkler C., et al. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog. Brain Res. 2000, 127:233-265.
4. Lindvall O., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. Ann. Neurol. 1992, 31:155-165.
5. Kordower J.H., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N. Engl. J. Med. 1995, 332:1118-1124.
6. Piccini P., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 1999, 2:1137-1140.
7. Mendez I., et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. J. Neurosurg. 2000, 92:863-869.
8. Freed C.R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 2001, 344:710-719.
9. Olanow C.W., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 2003, 54:403-414.
10. Mendez I., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nat. Med. 2008, 14:507-509.
11. Kordower J.H., et al. Lewy body-like pathology in longterm embryonic nigral transplants in Parkinson's disease. Nat. Med. 2008, 14:504-506.
12. Li J.Y., et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14:501-503.
13. Cooper O., et al. Lack of functional relevance of isolated cell damage in transplants of Parkinson's disease patients. J. Neurol. 2009, 256:S310-S316.
14. Lindvall O., Bjorklund A. Cell therapy in Parkinson's disease. NeuroRx 2004, 1:382-393.
15. Winkler C., et al. Cell transplantation in Parkinson's disease: how can we make it work?. Trends Neurosci. 2005, 28:86-92.
16. Piccini P., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
17. Winkler C., et al. Intranigral transplants of GABA-rich striatal tissue induce behavioural recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants. Exp. Neurol. 1999, 155:165-186.
18. Kirik D., et al. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J. Neurosci. 2001, 21:2889-2896.
19. Breysse N., et al. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J. Neurosci. 2007, 27:5849-5856.
20. Baker-Cairns B.J., et al. Contributions of donor and host blood vessels in CNS allografts. Exp. Neurol. 1996, 142:36-46.
21. Hagell P., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat. Neurosci. 2002, 5:627-628.
22. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain Res. Bull. 2005, 15:4-15.
23. Cenci M.A., Hagell P. Dyskinesias and neural grafting in Parkinson's disease. Restorative Therapies in Parkinson's Disease 2006, 184-224. Springer Science and Business Media. P. Brundin, C.W. Olanow (Eds.).
24. Olanow C.W., Fahn S. Fetal nigral transplantation as a therapy for Parkinson's disease. Restorative Therapies in Parkinson's Disease 2006, 93-118. Springer Science and Business Media. P. Brundin, C.W. Olanow (Eds.).
25. Carta M., et al. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Mov. Disord. 2010, 25(Suppl. 1):S174-S179.
26. Vinuela A., et al. Implanted reuptake-deficient or wild-type dopaminergic neurons improve ON L-Dopa dyskinesias without OFF-dyskinesias in a rat model of Parkinson's disease. Brain 2008, 131:3361-3379.
27. Jaber M., et al. The dopamine transporter: a crucial component regulating dopamine transmission. Mov. Disord. 1997, 12:629-633.
28. Maeda T., et al. Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-Dopa. Brain Res. 2005, 1046:230-233.
29. Carta M., et al. Dopamine released from 5-HT terminals is the cause of L-Dopa-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
30. Carlsson T., et al. Serotonin neuron transplants exacerbate L-Dopa-induced dyskinesias in a rat model of Parkinson's disease. J. Neurosci. 2007, 27:8011-8022.
31. Carlsson T., et al. Impact of grafted serotonin and dopamine neurons on development of L-Dopa-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain 2009, 132:319-335.
32. Nakao N., et al. Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease. J. Neurosci. 1998, 18:1806-1817.
33. Brundin P., et al. Research in motion: the enigma of Parkinson's disease pathology spread. Nat. Rev. Neurosci. 2008, 9:741-745.
34. Olanow C.W., et al. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 1996, 19:102-109.
35. Mukhida K., et al. Enhancement of sensorimotor behavioral recovery in hemiparkinsonian rats with intrastriatal, intranigral, and intrasubthalamic nucleus dopaminergic transplants. J. Neurosci. 2001, 21:3521-3530.
36. Redmond D.E., et al. Embryonic substantia nigra grafts in the mesencephalon send neurites to the host striatum in nonhuman primate after overexpression of GDNF. J. Comp. Neurol. 2009, 515:31-40.
37. Nikkhah G., et al. Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J. Neurosci. 1994, 14:3449-3461.
38. Starr P.A., et al. Intranigral transplantation of fetal substantia nigra allograft in the hemiparkinsonian rhesus monkey. Cell Transplant. 1999, 8:37-45.
39. Collier T.J., et al. Embryonic ventral mesencephalic grafts to the substantia nigra of MPTP-treated monkeys: feasibility relevant to multiple-target Grafting as a therapy for Parkinson's Disease. J. Comp. Neurol. 2002, 442:320-330.
40. Nikkhah G., et al. Dopaminergic microtransplants into the substantia nigra of neonatal rats with bilateral 6-OHDA lesions. I. Evidence for anatomical reconstruction of the nigrostriatal pathway. J. Neurosci. 1995, 15:3548-3561.
41. Bentlage C., et al. Reformation of the nigrostriatal pathway by fetal dopaminergic micrografts into the substantia nigra is critically dependent on the age of the host. Exp. Neurol. 1999, 159:177-190.
42. Aguayo A.J., et al. Fetal mesencephalic neurons survive and extend long axons across peripheral nervous system grafts inserted into the adult rat striatum. Neurosci. Lett. 1984, 45:53-58.
43. Dunnett S.B., et al. Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine rich nigral grafts and nigrostriatal 'bridge' grafts. Exp. Brain Res. 1989, 75:523-535.
44. Brecknell J.E., et al. Bridge grafts of FGF-4 secreting schwannoma cells promote functional axonal regeneration in the nigrostriatal pathway of the adult rat. Neuroscience 1996, 74:775-784.
45. Wang Y., et al. GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res. 1996, 286:225-233.
46. Wilby M.J., et al. A glial cell line-derived neurotrophic factor-secreting clone of the schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. J. Neurosci. 1999, 19:2301-2312.
47. Wictorin K., et al. Long distance directed axonal growth from human dopaminergic mesencephalic neuroblasts implanted along the nigrostriatal pathway in 6-hydroxydopamine lesioned adult rats. J. Comp. Neurol. 1992, 323:475-494.
48. Isacson O., et al. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat. Med. 1995, 1:1189-1194.
49. Isacson O., Deacon T.W. Specific axon guidance factors persist in the adult brain as demonstrated by pig neuroblasts transplanted to the rat. Neuroscience 1996, 75:827-837.
50. Gaillard A., et al. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol. Dis. 2009, 35:477-488.
51. Liang C.L., et al. Midbrain dopaminergic neurons in the mouse: co-localization with Calbindin-D28K and calretinin. Neuroscience 1996, 75:523-533.
52. Rogers J.H. Immunohistochemical markers in rat brain: colocalization of calretinin and calbindin-D28k with tyrosine hydroxylase. Brain Res. 1992, 587:203-210.
53. Thompson L.H., et al. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci. 2009, 4:625-638.
54. Isacson O., Deacon T. Neural transplantation studies reveal the brain's capacity for continuous reconstruction. Trends Neurosci. 1997, 20:477-482.
55. Sieber B.A., et al. Disruption of EphA/ephrin-a signaling in the nigrostriatal system reduces dopaminergic innervation and dissociates behavioral responses to amphetamine and cocaine. Mol. Cell. Neurosci. 2004, 26:418-428.
56. Yue Y., et al. Specification of distinct dopaminergic neural pathways: roles of the Eph family receptor EphB1 and ligand ephrin-B2. J. Neurosci. 1999, 19:2090-2101.
57. Lin L., Isacson O. Axonal growth regulation of fetal and embryonic stem cell derived dopaminergic neurons by Netrin-1 and Slits. Stem Cells 2006, 24:2504-2513.
58. Deschamps C., et al. Expression of ephrinA5 during development and potential involvement in the guidance of the mesostriatal pathway. Exp. Neurol. 2009, 219:466-480.
59. Wictorin K., Bjorklund A. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum-II. Cortical afferents. Neuroscience 1989, 30:297-311.
60. Wictorin K., et al. Connectivity of striatal grafts implanted into the ibotenic acid-lesioned striatum--III. Efferent projecting graft neurons and their relation to host afferents within the grafts. Neuroscience 1989, 30:313-330.
61. Wictorin K., et al. Extensive efferent projections of intra-striatally transplanted striatal neurons as revealed by a species-specific neurofilament marker and anterograde axonal tracing. Prog. Brain Res. 1990, 82:391-399.
62. Wictorin K., et al. Efferent projections to the host brain from intrastriatal striatal mouse-to-rat grafts: time course and tissue-type specificity as revealed by a mouse specific neuronal marker. Eur. J. Neurosci. 1991, 3:86-101.
63. Dunnett S.B., Iversen S.D. Neurotoxic lesions of ventrolateral but not anteromedial neostriatum in rats impair differential reinforcement of low rates (DRL) performance. Behav. Brain Res. 1982, 6:213-226.
64. Dunnett S.B., Iversen S.D. Sensorimotor impairments following localized kainic acid and 6-hydroxydopamine lesions of the neostriatum. Brain Res. 1982, 248:121-127.
65. Isacson O., et al. Graft-induced behavioral recovery in an animal model of Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:2728-2732.
66. Dunnett S.B., et al. The integration and function of striatal grafts. Prog. Brain Res. 2000, 127:345-380.
67. Peschanski M., et al. Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington's disease. Brain 2004, 127:1219-1228.
68. Freeman T.B., et al. Technical factors that influence neural transplant safety in Huntington's disease. Exp. Neurol. 2010, 10.1016/j.expneurol.2010.08.031.
69. Gaillard A., et al. Reestablishment of damaged adult motor pathways by grafted embryonic cortical neurons. Nat. Neurosci. 2007, 10:1294-1299.
70. Ourednik J., et al. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat. Biotechnol. 2002, 20:1103-1110.
71. Lin L.F., et al. GDNF: a glial cell line derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993, 260:1130-1132.
72. Sauer H., et al. Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:8935-8939.
73. Rosenblad C., et al. Intrastriatal glial cell line derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 1998, 82:129-137.
74. Brizard M., et al. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol. Dis. 2006, 21:90-101.
75. Rosenblad C., et al. Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 1996, 75:979-985.
76. Yurek D.M. Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp. Neurol. 1998, 153:195-202.
77. Lindvall O., Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 2009, 30:260-267.
78. Björklund A., Dunnett S.B. Dopamine neuron systems in the brain: an update. Trends Neurosci. 2007, 30:194-202.
79. Grealish S., et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 2010, 133:482-495.
80. Hanna J.H., et al. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. Cell 2010, 143:508-525.
81. Lindvall O., et al. Stem cell therapy for human neurodegenerative disorders - how to make it work. Nat. Med. 2004, 10:S42-S50.
82. Li J.Y., et al. Critical issues of clinical human embryonic stem cell therapy for brain repair. Trends Neurosci. 2008, 31:146-153.
83. Pruszak J., Isacson O. Molecular and cellular determinants for generating ES-cell derived dopamine neurons for cell therapy. Adv. Exp. Med. Biol. 2009, 651:112-123.
84. Kriks S., Studer L. Protocols for generating ES cell-derived dopamine neurons. Adv. Exp. Med. Biol. 2009, 651:101-111.
85. Arenas E. Towards stem cell replacement therapies for Parkinson's disease. Biochem. Biophys. Res. Commun. 2010, 21:152-156.
86. Hargus G., et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in Parkinsonian rats. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15921-15926.
87. Swistowski A., et al. Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. Stem Cells 2010, 28:1893-1904.
88. Jellinger K.A. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol. Chem. Neuropathol. 1991, 14:153-197.
89. Dunnett S.B., et al. Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions. Brain Res. 1987, 415:63-78.
90. Nikkhah G., et al. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 1993, 56:33-43.
91. Abrous D.N., et al. Dopamine-rich grafts in the neostriatum and/or nucleus accumbens: effects on drug-induced behaviours and skilled paw-reaching. Neuroscience 1993, 53:187-197.
92. Mendez I., et al. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J. Neurosci. 1996, 16:7216-7227.
93. Palmer M.R., et al. Intranigral transplantation of solid tissue ventral mesencephalon or striatal grafts induces behavioral recovery in 6-OHDA-lesioned rats. Brain Res. 2001, 890:86-99.
94. Kageyama G.H., Wong-Riley M.T.T. Histochemical localization of cytochrome oxidase in the hippocampus: correlation with specific neuronal types and afferent pathways. Neuroscience 1982, 7:2337-2361.
95. Wong-Riley M.M.T. Cytochrome oxidase: an endogenous metabolic marker for neuronal activity. Trends Neurosci. 1989, 12:94-101.
96. Alvarez-Dolado M. Cell fusion: biological perspectives and potential for regenerative medicine. Front. Biosci. 2007, 12:1-12.
97. Magavis S.S., Lois C. Transplanted neurons form both normal and ectopic projections in the adult brain. Dev. Neurobiol. 2008, 68:1527-1537.
98. MacLaren R.E., et al. Retinal repair by transplantation of photoreceptor precursors. Nature 2006, 444:203-207.